You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):控股子公司Gland Pharma擬在印度上市
格隆匯 11-01 18:10

格隆匯11月1日丨復星醫藥(600196.SH)公佈,公司於2019年11月1日召開第八屆董事會第八次會議(臨時會議),批准並擬提請股東大會批准Gland Pharma Limited公開發行股份並在印度國家證券交易所和孟買證券交易所上市交易。

Gland Pharma成立於1978年,總部位於印度海德拉巴,主要從事小分子注射劑仿製藥的開發及生產,董事長為LAU Yiukwan Stanley,首席執行官為Srinivas Sadu。Gland Pharma是印度第一家獲得美國FDA批准的注射劑藥品生產製造企業,並獲得全球各大法規市場的GMP認證,其業務收入主要來自於美國和歐洲。截至公告日,公司(通過控股子公司)合計持有Gland Pharma 74%的股權。

截至2018年12月31日,Gland Pharma的總資產約合人民幣62.4502億元,所有者權益約合人民幣47.9626億元,負債總額約合人民幣14.4876億元;2018年度,Gland Pharma實現營業收入約合人民幣19.1292億萬元,實現淨利潤約合人民幣2.8325億元。以上數據為合併口徑,含評估增值攤銷。

預計於境外上市完成後,Gland Pharma仍為公司控股子公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account